Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

The stock's fall snapped a four-day winning streak.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Beam Therapeutics Inc.’s BEAM share price has surged by 7.36%, which has investors questioning if this is right time to sell.

Medication company Viatris (NASDAQ:VTRS) in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... This data indicated resiliency in the labor market despite stock market uncertainty in April due to tariff concerns.

With its stock down 7.6% over the past three months ... the company made $0.09 in profit. Check out our latest analysis for Pfizer What Is The Relationship Between ROE And Earnings Growth? So far, ...